Chemistry:Entospletinib

Short description: Chemical compound

Entospletinib

Clinical data
Other names	GS-9973
Legal status
Legal status	Investigational
Identifiers
IUPAC name 6-(1H-Indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
CAS Number	1229208-44-9
PubChem CID	59473233
DrugBank	12121
UNII	6I3O3W6O3B
KEGG	D11209
Chemical and physical data
Formula	C23H21N7O
Molar mass	411.469 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1
InChI InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27) Key:XSMSNFMDVXXHGJ-UHFFFAOYSA-N

Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk). It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).